Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Up 11.5% - What's Next?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Get Free Report)'s share price shot up 11.5% during mid-day trading on Monday . The company traded as high as $0.45 and last traded at $0.43. 54,448,846 shares were traded during trading, a decline of 37% from the average session volume of 86,044,078 shares. The stock had previously closed at $0.38.

Analyst Ratings Changes

Separately, StockNews.com assumed coverage on shares of Tonix Pharmaceuticals in a research report on Saturday. They set a "hold" rating on the stock.

Tonix Pharmaceuticals Stock Performance

The company has a current ratio of 3.33, a quick ratio of 2.81 and a debt-to-equity ratio of 0.07. The company's 50 day moving average is $0.28 and its 200-day moving average is $0.28. The company has a market capitalization of $77.02 million, a P/E ratio of -0.01 and a beta of 2.02.

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, topping analysts' consensus estimates of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. The business had revenue of $2.82 million during the quarter, compared to the consensus estimate of $2.63 million. Equities analysts anticipate that Tonix Pharmaceuticals Holding Corp. will post -17.63 EPS for the current fiscal year.

Institutional Investors Weigh In On Tonix Pharmaceuticals

A hedge fund recently bought a new stake in Tonix Pharmaceuticals stock. PFG Investments LLC bought a new position in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 218,003 shares of the company's stock, valued at approximately $72,000. PFG Investments LLC owned approximately 0.12% of Tonix Pharmaceuticals at the end of the most recent quarter. 82.26% of the stock is currently owned by institutional investors.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.